Basic research for clinical treatment of neuropathic Gaucher disease by chemical chhaperones

点击翻译按钮获取中文摘要

There are no effective treatment for neurological manifestations in Gaucher disease. We found N-octyl-β-valienamine (NOV) could increase the protein level and enzyme activity of F213I mutant GBA in culture cells. We have tried to establish a model mouse expressing F213I protein, but failed to establish the mice. The NOV effects on normal mice were evaluated. No adverse effect was observed and GBA activity increased with increasing NOV dose in tissues. We also found new compounds, bicyclic nojirimycin analogues, show a chemical chaperone activity on mutant GBAs.